{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-24-023859","form_type":"8-K","ticker":"PURE","cik":"0001006028","company_name":"PURE BIOSCIENCE, INC.","filed_at":"2024-06-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:16.840981+00:00","generated_at":"2026-06-01T04:14:07.769545+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"PURE Bioscience Q3 net product sales $440K, net loss $857K; loss per share ($0.01)","bullets":["Net product sales $440,000 for Q3 FY2024, up 8% vs $406,000 in prior-year quarter.","Net loss $857,000; narrower than $876,000 in Q3 FY2023; net loss per share unchanged ($0.01).","For the nine months ended April 30, 2024, net product sales $1,483,000, net loss $2,594,000.","Company transitioning to distributor model; new Tier Pricing Agreement developed for distributor margins.","Social media platform engagement up 167% in past 90 days; followers up nearly 70%."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-24-023859","json":"https://secwatch.observer/filing/0001493152-24-023859.json","markdown":"https://secwatch.observer/filing/0001493152-24-023859.md","text":"https://secwatch.observer/filing/0001493152-24-023859.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1006028/000149315224023859/0001493152-24-023859-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1006028/000149315224023859/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T04:14:07.769545+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}